Fantagio Corp. to Co-Produce ‘The Docile Killer’ with Glain… Expanding Drama Production
Co-Production Agreement Signed for New Film in the "Innocent and Tragic Noir" Genre
Directed by Producer Lee Jeong-heum; Written by Joo Hwa-mi
Strengthening Competitiveness in Original IP and Diversifying the Content Portfolio
[Edaily Reporter Park Sun-Yeop ] Comprehensive entertainment company Fantagio Corp.(032800)is set to expand its drama production portfolio. Fantagio Corp. announced on the 1st that it has signed a co-production agreement with content production company Glain for the drama “The Docile Killer.” (Photo courtesy of Fantagio Corp.)
“The Docile Killer” is a pure and tragic noir drama that tells the story of a woman whose only plan in life was to be a model wife, who takes an unexpected job to survive in the world outside her sheltered life. Director Lee Jeong-heum will helm the project, and writer Ju Hwa-mi will pen the screenplay. This agreement is part of Fantagio Corp.’s strategy to expand its drama production pipeline. Fantagio Corp. plans to diversify its portfolio by producing content across various genres and strengthen its business competitiveness based on its own intellectual property (IP). Building on its foundation in actor and singer management, Fantagio Corp. has steadily expanded into the drama production sector. The company has accumulated production experience by participating in various projects, including tvN’s *Blind*, JTBC’s *Miracle Brothers*, MBC’s *Lovely Dog Today*, KBS2’s *Fantasy Love Song* and *Treat Me Roughly*, and SBS’s *Manager Kim*. Namgung Kyun, Chairman of Fantagio Corp., stated, “Based on the production capabilities we have built up over the years, we plan to expand our content portfolio and consistently present works across various genres.” He added, “Through the successful execution of projects, we will enhance the competitiveness of our in-house IP and strengthen our sustainable production foundation.”
As the number of small- and mid-sized firms and start-ups grows, competition for deals is intensifying. Compounded by corporate succession issues, small deals are emerging as a new investment opportun…
Celltrion’s Zimpentra. (Photo courtesy of Celltrion)
Celltrion(068270)Celltrion will conduct a global Phase 3 clinical trial in South Korea for “Zimpentra” (CT-P13 SC), a subcutaneous infliximab, …
LOTTE INNOVATE(286940)is partnering with Vietnamese IT firm CMC Group to expand into new local businesses, such as data centers and electric vehicle charging. The company plans to leverage its existin…